Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026)

Trevi Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $498000.0 for Q1 2026.

• In Q1 2026, Net Cash Flow rose 103.38% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $38000.0 (down 99.32% YoY), while the FY2025 annual figure was -$15.2 million, down 993.12% from the prior year.
• Net Cash Flow for Q1 2026 stood at $498000.0, up from -$38.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $97.7 million in Q2 2025, with the low at -$60.2 million in Q3 2025.
• The 5-year median for Net Cash Flow is $498000.0 (2026), against an average of $2.2 million.
• Peak annual rise in Net Cash Flow reached 11619.34% in 2025, while the deepest fall reached 2048.49% in 2025.
• Trevi Therapeutics' Net Cash Flow stood at -$54.0 million in 2022, then soared by 111.91% to $6.4 million in 2023, then surged by 180.55% to $18.0 million in 2024, then sank by 310.34% to -$38.0 million in 2025, then soared by 101.31% to $498000.0 in 2026.
• Business Quant data shows TRVI's Net Cash Flow at $498000.0 in Q1 2026, -$38.0 million in Q4 2025, and -$60.2 million in Q3 2025.